MedTrace Logo

Impact of Hydroxocobalamine on Outcome of Smoke Inhalation Injury Admitted to the ICU

NCT03558646 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 739

Last updated 2019-04-04

No results posted yet for this study

Summary

In Europe, hydroxocobalamin (cyanokit) has been used for suspicion of cyanide intoxication associated with the inhalation of fire smoke (1). However, the impact of hydroxocobalamin on outcome has never been thoroughly evaluated. While hydroxocobalamin has long been presented as being side-effect free, recent data suggest that in patients with severe burns, its use was associated with the occurrence of acute renal failure by intra tubular precipitation of oxalate crystals (2, 3). The purpose of this observational study is to investigate the association between use of hydroxocobalamin and outcome after smoke inhalation.

Conditions

  • Smoke Inhalation Patients

Interventions

OTHER

There is no intervention planned (observational)

There is no intervention planned (observational)

Sponsors & Collaborators

  • Saint-Louis Hospital, Paris, France

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-01
Primary Completion
2018-12-31
Completion
2019-02-01

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03558646 on ClinicalTrials.gov